Viktor Grünwald

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Viktor Grünwald
Apr 26, 2025, 19:27 | Insight
Viktor Grünwald: German real-world cohort of LEN+PEM in mRCC patients
Viktor Grünwald, Professor of Urologic Oncology at University Hospital Essen, shared on LinkedIn: "Just out,…
Jan 4, 2025, 15:13 | Science
Marco Donia: Modified Classification for Progressive Disease in Immunotherapy
Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital, shared a recent paper…
Dec 17, 2024, 06:06 | Blog
Enrique Grande: NECTIN4 amplifications appear in ~25% of metastatic cases of urothelial carcinoma
Enrique Grande, Associate Professor at Francisco de Vitoria University, shared on LinkedIn: “New insights in…
Dec 4, 2024, 15:46 | Blog
The CARE1 Principal Investigators team at SOGUG24
CARE1 Project shared on LinkedIn: "The CARE1 Principal Investigators team was proudly present at SOGUG24!…
Nov 12, 2024, 16:41 | Insight
Enrique Grande: Pre-treatment metastatic biopsy by Niklas Klümper et al.
Enrique Grande, Head of Oncology at MD Anderson Cancer Center, shared a post on X…
Nov 2, 2024, 21:06 | Insight
Sabine Brookman-May: Are pre-treatment biopsies the way to go in mUC?
Sabine Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared…
Oct 31, 2024, 15:25 | Insight
Markus Eckstein: A step towards precision oncology for urothelial cancer
Markus Eckstein, Senior Physician/Pathologist and Clinician Scientist at the University Hospital Erlangen, shared a post…
Oct 31, 2024, 15:03 | Insight
Niklas Klümper: Pre-treatment metastatic biopsy for urothelial cancer
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the…
Oct 3, 2024, 14:17 | Dialogues
ASCO24 Updates: Viktor Grünwald on CLEAR Study: Lenvatinib and Pembrolizumab for Kidney Cancer
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Sep 14, 2024, 13:51 | Blog
Viktor Grunwald: Real-world cabozantinib after ICI
Viktor Grunwald, Professor of Interdisciplinary Genitourinary (GU) Oncology at the University Hospital Essen, shared a…
Aug 1, 2024, 09:08 | Insight
Piotr Wysocki: Combining PSMA-PET with PROMISE improves survival predictions for prostate cancer
Piotr Wysocki recently posted on LinkedIn: "A recent multicentre retrospective study aimed to evaluate the effectiveness…
Jul 31, 2024, 10:58 | Insight
Yüksel Ürün: PSMA-PET by PROMISE effective in high/low-risk stratification in prostate cancer
Yüksel Ürün shared on X about a recent paper titled "Combining PSMA-PET and PROMISE to re-define…
Apr 30, 2024, 11:17 | Insight
New Paper Alert! Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer
Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer Authors: Niklas Klümper, MD,…
Apr 26, 2024, 17:55 | Insight
Piotr Wysocki: NECTIN4 amplification is a predictive factor for enfortumab vedotin efficacy
Piotr Wysocki recently shared on LinkedIn: "Kluemper et al. published results of a study evaluating NECTIN4…
Apr 12, 2024, 12:37 | Insight
Niklas Klümper: Happy to share our commentary about EV-302
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the…
All: 15 Posts: 1 - 100
Special Coverage